

# Letters to the Editor

Send letters to Kenny Lin, MD, Associate Medical Editor for *AFP* Online, e-mail: [afplet@aafp.org](mailto:afplet@aafp.org), or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, telephone number, and fax number. Letters should be fewer than 500 words and limited to six references and one table or figure.

Letters submitted for publication in *AFP* must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

## Responses to Article Regarding Contraception Choices in Women

**Original Article:** Contraception Choices in Women with Underlying Medical Conditions

**Issue Date:** September 15, 2010

**Available at:** <http://www.aafp.org/afp/2010/0915/p621.html>

TO THE EDITOR: This article did not discuss other effective family planning choices for couples who do not desire pregnancy. All of the hormonal contraceptives mentioned in the article are not without considerable risk of adverse effects, in addition to the increased risks posed by underlying comorbidities.

Physicians should be knowledgeable about nonpharmacologic methods of birth regulation, including fertility awareness-based methods, which involve women observing their own biomarkers of fertility and infertility through each menstrual cycle. My clinical experience with appropriately selected couples using the Creighton Model FertilityCare System to avoid pregnancy has been excellent. A meta-analysis of five studies of nearly 2,000 couples using the Creighton method<sup>1</sup> and a more recent review<sup>2</sup> found pregnancy rates of 0.5 percent with perfect use and 17.1 percent with typical use after 12 months. These figures are at least comparable to those of hormonal contraceptives.

JEAN GOLDEN-TEVALD, DO, CFCMC, FCP  
Pittstown, N.J.  
E-mail: [jeantev@embarqmail.com](mailto:jeantev@embarqmail.com)

Author disclosure: No relevant financial affiliations to disclose.

### REFERENCES

1. Hilgers TW, Stanford JB. Creighton Model NaProEducation Technology for avoiding pregnancy. *J Reprod Med*. 1998;43(6):495-502.
2. Pallone SR, Bergus GR. Fertility awareness-based methods: another option for family planning [published correction appears in *J Am Board Fam Med*. 2009;22(5):596]. *J Am Board Fam Med*. 2009;22(2):147-157.

TO THE EDITOR: In this article, the authors present hormonal contraceptive options for family physicians to recommend to women with specific chronic medical conditions. The omission of any effective natural methods of fertility regulation perpetuates a general gap of knowledge among physicians unless they pursue specialized studies in this field.

The utility and wide applicability of a natural method of fertility regulation for purposes of avoiding pregnancy was established by the multicenter trial of the World Health Organization (WHO) in the 1980s. The WHO defines natural family planning (NFP) as “methods for planning and preventing pregnancy by observation of the naturally occurring signs and symptoms of the fertile and infertile phases of the menstrual cycle, with the avoidance of intercourse during the fertile phase if pregnancy is to be avoided.”<sup>1</sup>

Counseling in natural methods of fertility regulation is currently being provided by a growing number of trained physicians, nurse practitioners, and allied health professionals. In the United States, methods include the Billings Ovulation Method, the Creighton Model FertilityCare System, the symptothermal methods, and the Marquette Method. These family planning methods should not be confused with calendar rhythm method and are not dependent on the regularity of a woman's cycle.

Population-based surveys have shown a significant interest in NFP—approximately 25 percent of women and 40 percent of men are interested in using NFP to avoid pregnancy, and 33 percent of women are interested in using NFP to conceive. This interest is not associated with religion, education, age, or income level.<sup>2,3</sup>

Natural methods have been evaluated for their use effectiveness to avoid pregnancy and have been found to be highly reliable.<sup>4</sup> Data were presented to the U.S. Department of Health and Human Services when the International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM), ►



was updated to include “counseling and instruction in natural family planning to avoid pregnancy” (V25.04), and “procreative counseling and advice using natural family planning” (V26.41).<sup>5</sup> An overview presentation titled “Natural Methods of Family Planning” is available at [http://www.cdc.gov/nchs/data/icd9/att4\\_NFP\\_mar06.pdf](http://www.cdc.gov/nchs/data/icd9/att4_NFP_mar06.pdf).

Recognizing that many hormone-based contraceptives and devices have mechanisms of action potentially interrupting a pregnancy in embryonic development,<sup>6</sup> a growing number of family physicians have been pursuing training in natural methods of fertility regulation. Women who learn natural methods actively track their cycles, gaining practical day-to-day knowledge of their times of fertility and infertility, and the ability to recognize gynecologic abnormalities earlier.

Although hormonal contraceptives carry a known burden of risk, natural methods are completely free of medical adverse effects. Unfortunately, without training or practical exposure to their successful use, most physicians are ill-equipped to recommend natural methods.

We invite clinicians to develop confidence and competence in recommending a non-contraceptive family planning system by attending an annual meeting of the American Academy of FertilityCare Professionals (<http://www.aafcp.org>) or by contacting a local NFP center through FertilityCare Centers of America (<http://www.fertilitycare.org>); Billings Ovulation Method Association-USA (<http://www.boma-usa.org>); the Couple to Couple League for Natural Family Planning (<http://www.ccli.org>); or the Marquette Model of Natural Family Planning (<http://nfp.marquette.edu>).

ROBERT F. CONKLING, MD, FCP  
Manassas, Va.  
E-mail: [quovadis.lifecoach@gmail.com](mailto:quovadis.lifecoach@gmail.com)

LESLIE A. CHORUN, MD, CFCMC, FCP  
Kansas City, Kan.  
E-mail: [st.lydwina@gmail.com](mailto:st.lydwina@gmail.com)

Author disclosure: No relevant financial affiliations to disclose.

## REFERENCES

1. World Health Organization. Family Planning and Population division. *Natural Family Planning: What Health*

*Workers Need to Know*. Geneva, Switzerland: World Health Organization, 1995.

2. Stanford JB, Lemaire JC, Thurman PB. Women's interest in natural family planning. *J Fam Pract*. 1998; 46(1):65-71.
3. Stanford JB, Hutchinson AG, Payne JG. Utah couples' potential use of natural family planning. *Utah's Health: An Annual Review*. 2003;9:40-45.
4. Hilgers TW, Stanford JB. Creighton Model NaProEducation technology for avoiding pregnancy. Use effectiveness. *J Reprod Med*. 1998;43(6):495-502.
5. ICD-9-CM Supplementary classification of factors influencing health status and contact with health services, 682, 683. [ftp://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Publications/ICD9-CM/2007/Dtab08.zip](ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD9-CM/2007/Dtab08.zip).
6. Larimore WL, Stanford JB. Postfertilization effects of oral contraceptives and their relationship to informed consent. *Arch Fam Med*. 2000;9(2):126-133.

TO THE EDITOR: In this article, the authors recommend progestin-only methods of contraception for women with a history of atherosclerotic arterial disease, venous thromboembolism, or other contraindications to the estrogens found in combination oral contraceptives. They discuss the use of depot medroxyprogesterone acetate (Depo-Provera), a long-acting injectable progestin; Implanon, a subdermally implanted single-rod device that releases a progestin; and Mirena, a levonorgestrel-containing intra-uterine contraceptive system. The authors omitted any discussion of progestin-only oral contraceptives (i.e., the “mini-pill”). This contraceptive is known as the mini-pill because the dose of norethindrone is substantially lower than the progestin dose found in any combination oral contraceptive. Many physicians consider the mini-pill the most reasonable first choice for women considering progestin-only contraception because it can be quickly discontinued if the patient experiences intolerable adverse effects. If the mini-pill is well-tolerated, women can consider a long-acting delivery system. Norethindrone is the only progestin-only oral contraceptive approved in the United States. It is available at a dosage of 0.35 mg per day, in 28-day packs, to be taken continuously with no pill-free interval.

DAVID L. KELLER, MD  
Torrance, Calif.  
E-mail: [David.Keller@Providence.Org](mailto:David.Keller@Providence.Org)

Author disclosure: No relevant financial affiliations to disclose. ■